Filing Flows

Filing Flows › Companies › Coherus Oncology › Cash flow

Coherus Oncology cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$62.1M in Q2 2026 · −$186M over twelve months

Operating cash flow−$62.1M
Free cash flow−$62.1M
Cash conversion cycle-38 days

Analysis

In Q2 2026, Coherus Oncology generated −$62.1M of operating cash flow. That is $15.5M less than in Q2 2025 (−$46.6M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$186M; the largest uses were operating cash flow ($186M), other investing ($9.8M), net borrowing (+) / repaid (−) ($121K); besides operations, cash came from other financing ($61.7M), shares issued ($367K); the cash balance fell by $134M.

Operating cash flow was −$62.1M against net income of −$20.6M. The largest differences: other operating capital −$38.9M, receivables +$8.2M, prepaid and other assets +$7.6M.

Its cash conversion cycle was -38 days (receivables 114 + inventory 113 − payables 264): suppliers fund its working capital.

Free cash flow

Coherus Oncology: free cash flow by quarterCoherus Oncology: free cash flow by quarter−$62.0MQ3 2024$28.6MQ4 2024−$25.8MQ1 2025−$46.6MQ2 2025−$46.3MQ3 2025−$19.7MQ4 2025−$57.9MQ1 2026−$62.1MQ2 2026
Operating cash flow less capital spending.
Coherus Oncology: operating cash flow against capital spendingCoherus Oncology: operating cash flow against capital spendingOperating cash flowCapital spending−$62.0M$0Q3 2024$28.6M$0Q4 2024−$25.8M$0Q1 2025−$46.6M$0Q2 2025−$46.3M$0Q3 2025−$19.7M$0Q4 2025−$57.9M$0Q1 2026−$62.1M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$62.1M, Capital spending $0.

Capital allocation, year by year

Coherus Oncology: where the cash came from (up) and went (down), by fiscal yearCoherus Oncology: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$37.4MFY2021: Net borrowing −$81KFY2021: Shares issued $51.3MFY2021: Capital spending −$1.3M$51.3MFY2021FY2022: Operating cash flow −$241MFY2022: Net borrowing $159MFY2022: Shares issued $7.0MFY2022: Capital spending −$2.0M$166MFY2022FY2023: Operating cash flow −$175MFY2023: Net borrowing −$145KFY2023: Shares issued $694KFY2023: Capital spending −$286K$694KFY2023FY2024: Operating cash flow −$20.4MFY2024: Net borrowing −$260MFY2024: Shares issued $1.7M$1.7MFY2024FY2025: Operating cash flow −$139MFY2025: Net borrowing −$233MFY2025: Shares issued $353K$353KFY2025
Over these 5 years operating cash flow totalled −$612M; the largest uses were operating cash flow ($612M) and net borrowing ($494M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$105M
Debtnone
Net cash$105M
Cash runway7 months

Coherus Oncology is burning cash: its operations consume cash, a free cash flow of −$186M a year at the current rate against $105M of cash and investments: a runway of about 7 months before any new financing.

Where the cash came from and went

Coherus Oncology: sources (+) and uses (−) of cash, Q2 2026Coherus Oncology: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$62.1MCash drawn (+) / kept (−)$32.3MOther investing$29.6MOther financing$144K
Coherus Oncology: sources (+) and uses (−) of cash, TTM to Q2 2026Coherus Oncology: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$186MCash drawn (+) / kept (−)$134MOther financing$61.7MOther investing−$9.8MShares issued$367KNet borrowing (+) / repaid (−)−$121KTaxes on employees’ shares−$115K

From profit to cash

Coherus Oncology: net income to operating cash flow, Q2 2026Coherus Oncology: net income to operating cash flow, Q2 2026Net income−$20.6MDepreciation & amortization$862KStock-based pay$2.6MReceivables$8.2MInventory$437KPayables$1.7MAccrued liabilities−$1.3MPrepaid and other assets$7.6MOther operating capital−$38.9MOperating cash flow−$62.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 2026114113264-38
Q1 202614694252-12
Q4 20259859396-239
Q3 20255781773-635
Q2 20252911081053-654
Q1 202510171311177-28
Q4 202416598678421684
Q3 20242606185116642793

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$62.1M——$32.3M−$62.1M
Q1 2026−$57.9M—$53.6M−$26.4M−$57.9M
Q4 2025−$19.7M—$165K$14.5M−$19.7M
Q3 2025−$46.3M——$114M−$46.3M
Q2 2025−$46.6M——−$134M−$46.6M
Q1 2025−$25.8M——$43.6M−$25.8M
Q4 2024$28.6M——−$28.3M$28.6M
Q3 2024−$62.0M−$141K—$61.7M−$62.0M

Coherus Oncology: income statement and cash flow

Coherus Oncology, Q2 2026: revenue $14.3M (+40% year over year), operating margin -226.0%. The chart follows the revenue to costs, profit and cash.

Coherus Oncology: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.